Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov ID: NCT00606684

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00606684. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study B2C111045, A Dose-Finding Study of GW642444 Versus Placebo in Patients With COPD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)

Study identification

NCT ID
NCT00606684
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
602 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2008 (Type not available)
Primary completion
Oct 2008 (Actual)
Completion
Oct 2008 (Actual)
Last update posted
Dec 16, 2016

2008

United States locations

U.S. sites
49
U.S. states
20
U.S. cities
48
Facility City State ZIP Site status
GSK Investigational Site Florence Alabama 35630 —
GSK Investigational Site Jasper Alabama 35501 —
GSK Investigational Site Montgomery Alabama 36109 —
GSK Investigational Site Fullerton California 92835 —
GSK Investigational Site Lakewood California 90712 —
GSK Investigational Site Los Angeles California 90095-1752 —
GSK Investigational Site Rancho Mirage California 92270 —
GSK Investigational Site Sepuldeva California 91343 —
GSK Investigational Site Upland California 91786 —
GSK Investigational Site Newark Delaware 19713 —
GSK Investigational Site Brandon Florida 33511 —
GSK Investigational Site DeLand Florida 32720 —
GSK Investigational Site Miami Florida 33136 —
GSK Investigational Site Tampa Florida 33613 —
GSK Investigational Site Marietta Georgia 30060 —
GSK Investigational Site Carmel Indiana 46032 —
GSK Investigational Site Elkhart Indiana 46515 —
GSK Investigational Site New Albany Indiana 47150 —
GSK Investigational Site Lafayette Louisiana 70503 —
GSK Investigational Site Sunset Louisiana 70584 —
GSK Investigational Site Detroit Michigan 48201-2018 —
GSK Investigational Site Livonia Michigan 48152 —
GSK Investigational Site Saint Charles Missouri 63301 —
GSK Investigational Site St Louis Missouri 63122 —
GSK Investigational Site St Louis Missouri 63141 —
GSK Investigational Site Butte Montana 59701 —
GSK Investigational Site Summit New Jersey 07091 —
GSK Investigational Site Elmira New York 14901 —
GSK Investigational Site Larchmont New York 10538 —
GSK Investigational Site Charlotte North Carolina 28207 —
GSK Investigational Site Greenville North Carolina 27834 —
GSK Investigational Site Raleigh North Carolina 27607 —
GSK Investigational Site Statesville North Carolina 28625 —
GSK Investigational Site Cincinnati Ohio 45231 —
GSK Investigational Site Medford Oregon 97504 —
GSK Investigational Site Portland Oregon 97220 —
GSK Investigational Site Philadelphia Pennsylvania 19140 —
GSK Investigational Site Charleston South Carolina 29406-7108 —
GSK Investigational Site Gaffney South Carolina 29340 —
GSK Investigational Site Greenville South Carolina 29615 —
GSK Investigational Site Spartanburg South Carolina 29303 —
GSK Investigational Site Union South Carolina 29379 —
GSK Investigational Site Corsicana Texas 75110 —
GSK Investigational Site Dallas Texas 75216 —
GSK Investigational Site Houston Texas 77030 —
GSK Investigational Site Waco Texas 76712 —
GSK Investigational Site South Burlington Vermont 05403 —
GSK Investigational Site Abingdon Virginia 24210 —
GSK Investigational Site Richmond Virginia 23225 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00606684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2016 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.